HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?

Vincenzo Arena, Ilaria Pennacchia, Fabio Maria Vecchio, Arnaldo Carbone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
Lingua originaleEnglish
pagine (da-a)31-35
Numero di pagine5
RivistaApplied Immunohistochemistry and Molecular Morphology
Volume23
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Cell Membrane
  • Female
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Middle Aged
  • Protein Transport
  • Receptor, ErbB-2
  • Reference Standards
  • Research Design
  • Trastuzumab

Fingerprint

Entra nei temi di ricerca di 'HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?'. Insieme formano una fingerprint unica.

Cita questo